What Is ER-100? OSK Reprogramming and Optic Nerve Research

October 3, 2026

What Is ER-100?

ER-100 is an investigational gene therapy designed to restore function in retinal ganglion cells through partial epigenetic reprogramming. Its scientific foundation is controlled expression of three transcription factors: OCT4, SOX2 and KLF4, collectively called OSK. The current clinical program concerns optic neuropathies, specifically open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, or NAION. It is not an established treatment for these conditions. [1]

Chemical Identity of ER-100

OSK stands for OCT4, SOX2 and KLF4. These proteins are transcription factors: regulators that influence gene expression. Their combination is drawn from cellular reprogramming research. The familiar four-factor combination also includes c-MYC; OSK omits it. A PubMed-indexed review discusses that omission in relation to the oncogenic concerns associated with c-MYC. [4]

Removing one factor does not settle every safety question. The scientific challenge is controlling the extent and persistence of reprogramming while preserving cell identity and normal tissue behavior. Whether a strategy avoids unwanted changes must be tested rather than inferred from its name.

In the 2020 mouse study, OSK expression was associated with restored youthful methylation patterns and transcriptomes in retinal ganglion cells. The benefits depended on TET1 and TET2, enzymes involved in DNA demethylation. This dependence supported a mechanistic connection between epigenetic regulation and the observed regeneration and visual findings. It did not establish that every age-related change is reversible. [2]

Molecular Data

Property Value
CAS# Not listed in PubChem
PubChem ID Not listed in PubChem
Molecular Formula Not listed in PubChem
Molecular Weight Not listed in PubChem
Exact Mass Not listed in PubChem
IUPAC Name Not listed in PubChem
InChIKey Not listed in PubChem
SMILES Not listed in PubChem
Molecular Class Investigational gene therapy delivering the transcription factors OCT4, SOX2 and KLF4 (OSK)

PubChem has no compound record for ER-100, so identifiers PubChem would verify are marked “Not listed in PubChem”. No structure image is shown.

The central question is unusually ambitious: can a damaged or aging nerve cell recover useful function by changing how it reads its genetic information, rather than replacing the cell? Animal studies provide reasons to investigate that question. An early clinical trial is now testing whether the approach has an acceptable safety profile. These are different stages of evidence, and keeping them separate is essential to understanding ER-100.

Why Study the Optic Nerve and Retinal Ganglion Cells?

Retinal ganglion cells are neurons in the retina whose axons form the optic nerve. Their activity connects retinal information with the brain’s visual pathways. When these cells or their axons are damaged, visual function can deteriorate. This makes both cellular function and axonal integrity important research targets, rather than treating vision as a single measurement. [2,3]

The ER-100 trial includes two distinct optic nerve conditions. Open-angle glaucoma involves progressive optic neuropathy; NAION involves an ischemic injury associated with impaired blood supply to the optic nerve. The protocol studies glaucoma first, with a subsequent NAION cohort. Sharing a vulnerable cell population does not mean that the two diseases have identical causes or will respond identically. [1]

This distinction also limits the phrase “eye rejuvenation.” ER-100 is not being established as a solution to every cause of declining eyesight. The registered study concerns specified optic neuropathies, not a general reversal of all retinal, lens or corneal aging.

What Does Partial Epigenetic Reprogramming Mean?

Epigenetics concerns regulation of gene activity without rewriting the underlying DNA sequence. DNA methylation is one of the features researchers can measure when studying aging and cellular identity. In the foundational vision study, investigators examined whether older or injured cells retained information that could support a more youthful pattern of gene expression. [2]

A useful distinction is between the genetic instructions and the regulation of those instructions. Cells can share genetic information while expressing different sets of genes. Epigenetic reprogramming attempts to change aspects of that regulatory state. The word “partial” matters: the intended outcome is improved function while retaining the specialized identity of a retinal neuron, not making it into a pluripotent stem cell.

That is an experimental objective, not a guarantee. A younger-looking methylation signature, restored gene-expression patterns and better visual performance are related but different findings. An epigenetic clock is a measurement model, not direct proof that a nerve has repaired its connections. Strong evidence needs molecular observations and functional outcomes to support one another. [2,4]

For ER-100, the registry describes a modified adeno-associated viral vector carrying genetic instructions for OSK. It describes the approach as changing gene-expression patterns rather than altering existing genes. This is gene therapy, but it is not described as gene editing that corrects a particular inherited mutation. [1]

What Did the Preclinical Vision Studies Find?

The foundational Nature paper by Lu and colleagues, published in 2020, reported three important categories of results in mice. OSK promoted axon regeneration after optic nerve injury, improved visual function in a glaucoma model and reversed aspects of age-associated visual decline. The authors also reported changes toward youthful DNA methylation and gene-expression patterns in retinal ganglion cells. [2]

These experiments answer different questions. An injury model tests regenerative capacity after a defined insult. A glaucoma model examines function after experimentally induced disease-related damage. Aging experiments address whether some functional decline can shift in older tissue. Their convergence is scientifically interesting, but no single model reproduces the full complexity of clinical optic neuropathy.

A later study, indexed in PubMed as “Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma,” extended the observation period. Its abstract reported sustained recovery with prolonged OSK expression, persistence of some improvement after expression stopped and later diminution of the benefit. It also reported no adverse effects on retinal structure or body weight under the mouse conditions examined. [3]

These findings make durability a central question. Recovery at one time point and stable benefit over years are not equivalent outcomes. Likewise, an absence of particular adverse findings in mice cannot establish long-term clinical safety. The preclinical papers support testing the biological hypothesis; they do not demonstrate that ER-100 restores an optic nerve in a completed clinical efficacy trial.

What Is the ER-100 Clinical Trial Status?

As checked on November 7, 2026, ClinicalTrials.gov lists NCT07290244 as recruiting and identifies it as a Phase 1 study. The registry describes a non-randomized, open-label, sequential-cohort design with an estimated enrollment of 18 participants: 12 with open-angle glaucoma and six with NAION. Its recorded actual start date is March 2, 2026. [1]

The estimated primary completion is May 2027, with overall study completion estimated for March 2032. These are planning dates, not promises of completed results or approval. The protocol includes follow-up through five years, reflecting the importance of observing delayed effects as well as early tolerability.

The principal focus is safety and tolerability. Recorded assessments include adverse events, laboratory findings, eye pressure and several measures of visual function and retinal structure. The registry also includes immune-response assessments. Functional measures include visual fields, contrast sensitivity and pattern electroretinography; structural measures include retinal nerve fiber and ganglion cell layer thickness. [1]

The registry had no posted results at this check. A trial registration describes the study and its planned measurements. It should not be read as a published finding that the candidate works.

How Should Different Measures of Vision Be Interpreted?

The trial’s range of measurements is important because vision is not a single biological output. Visual acuity asks about resolving detail on a chart. Visual-field testing maps sensitivity across locations. Contrast sensitivity addresses differences between light and dark. An improvement on one measure does not automatically imply equal improvement on the others. The registry separates these outcomes rather than treating them as synonyms. [1]

Pattern electroretinography adds a functional signal from the retina. Optical coherence tomography provides structural information, including the thickness of layers containing ganglion cell bodies and nerve fibers. These approaches can complement one another, but they do not answer exactly the same question. A thickness measurement alone does not demonstrate that new axons have formed working connections to the brain.

The most persuasive future evidence would connect meaningful, repeatable functional changes with a coherent biological explanation and an acceptable safety record. It would also distinguish an early shift from a durable effect. That is why the planned long-term observation is scientifically important even if early summaries attract more attention.

There is also a difference between an epigenetic mechanism and a clinical endpoint. Demonstrating that a molecular pathway participates in regeneration in mice helps explain why a therapy might work. Demonstrating that a clinical candidate produces reliable benefit requires its own evidence. Neither type of study can replace the other, and the strength of the ER-100 story depends on maintaining that distinction.

What Has Been Reported About Early Clinical Observations?

An October 8, 2026 sponsor press release described interim observations in three glaucoma participants through Day 56. It reported no serious adverse events, adverse events of special interest or dose-limiting toxicities in that initial group. It also reported preliminary improvement on visual-field testing in two participants. These are sponsor-reported interim findings, not results posted in the registry or a completed peer-reviewed efficacy analysis. [5]

The small sample and short observation window sharply limit interpretation. An open-label study with comparisons to baseline does not provide the same protection against bias and measurement variability as a randomized, masked comparison. A visual-field signal is a reason to investigate further, not confirmation that an optic nerve has regenerated.

The next meaningful questions include reproducibility, consistency across different visual tests, durability and longer-term safety. Findings in glaucoma cannot simply be assigned to NAION before that population is adequately studied. The current evidence supports describing ER-100 as an early clinical investigation of a promising biological idea, not as proven vision restoration.

How Does This Connect with Eye-Health Research in the Modern Aminos Catalog?

The closest catalog connection is Choline, a separate research topic involving retinal and visual-pathway function. Modern Aminos lists Choline. This connection is based on the shared scientific focus on optic nerve function, not a claim that Choline performs OSK reprogramming or substitutes for ER-100.

A PubMed-indexed randomized, double-masked, placebo-controlled study followed 80 participants with progressing open-angle glaucoma. It reported differences favoring Choline in a central visual-field measure and retinal nerve fiber layer change, while the broader 24-2 visual-field comparison did not reach conventional statistical significance. This mixed pattern is more informative than describing every outcome as positive. [6]

Those findings concern the study’s specific investigational formulation and setting. They do not establish equivalent effects for a catalog product. The useful bridge is the research question: how can retinal ganglion cell function be preserved or supported? ER-100 explores epigenetic reprogramming; Choline belongs to a distinct line of investigation. Neither should be presented as interchangeable with the other.

References

  1. ClinicalTrials.gov: NCT07290244
  2. Lu et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature, 2020. PMID 33268865
  3. Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma. PMID 38060815
  4. Cellular reprogramming and epigenetic rejuvenation. PMID 34488874
  5. Sponsor press release: first-in-human interim data, October 8, 2026
  6. Can Treatment With Choline Eyedrops Reduce Progression in Glaucoma? PMID 32541370

Frequently Asked Questions

Is ER-100 a Peptide?

No. ER-100 is an investigational gene therapy based on OSK expression, not a peptide. OSK refers to the transcription factors OCT4, SOX2 and KLF4.

Can ER-100 Reverse Glaucoma?

Animal studies reported recovery of visual function with OSK, but ER-100 has not established reversal of glaucoma in a completed clinical efficacy trial. Its current registered study is Phase 1.

What Conditions Is ER-100 Being Studied for?

The registered ER-100 study concerns open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, also called NAION. These are distinct conditions affecting the optic nerve.

Does ER-100 Change DNA?

The registry describes ER-100 as providing genetic instructions for OSK without altering existing genes. Its intended effect is epigenetic regulation of gene expression, not correction of a DNA mutation.

What Is the ER-100 Trial Number?

The ClinicalTrials.gov identifier is NCT07290244. As checked on November 7, 2026, the registry lists the Phase 1 study as recruiting, with no posted results.

Is Partial Reprogramming the Same as Making Stem Cells?

No. Partial reprogramming aims to recover aspects of cellular function while retaining specialized identity. Producing pluripotent stem cells would be a different outcome, not the intended retinal goal.

0